Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Centre for Minimal Access Surgery (CMAS), Division of General Surgery, Department of Surgery, McMaster University St. Joseph's Healthcare, 50 Charlton Avenue East Hamilton, Hamilton, ON, L8N 4A6, Canada.
Surg Endosc. 2019 Jun;33(6):1710-1720. doi: 10.1007/s00464-019-06701-5. Epub 2019 Feb 14.
Achalasia is a rare primary esophageal dysmotility disorder in children. Peroral endoscopic myotomy (POEM) is a novel endoscopic technique which has shown promising results for treating achalasia in adults. However, limited data on efficacy and safety in pediatric patients are available. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of POEM in pediatric achalasia.
We searched MEDLINE, Embase, PubMed, and Web of Science databases through July 2018. Studies were eligible for inclusion if they conducted POEM in pediatric patients. Main outcomes were Eckardt score and lower esophageal sphincter (LES) pressure before and after POEM. Secondary outcomes were clinical success rate and adverse events associated with POEM. Two reviewers independently reviewed the studies, collected data, and assessed quality of evidence using Methodological Index for Non-Randomized Studies (MINORS). Pooled estimates were calculated using random effects meta-analyses. Heterogeneity was quantified using the inconsistency statistic, and funnel plot was used to assess publication bias.
A total of 12 studies with 146 pediatric patients (53.68% female) underwent POEM for the treatment of achalasia (mean duration of disease of 19.48 months). There was a significant reduction in Eckardt score by 6.88 points (Mean Difference (MD) 6.88, 95% confidence interval (CI), 6.28-7.48, P < .001) and LES pressure by 20.73 mmHg (MD 20.73, 95% CI, 15.76-25.70, P < .001) following POEM. At least 93% of the patients experienced improvement or resolution of achalasia symptoms both short and long terms after POEM, with small proportion of patients experiencing minor adverse effects which could be managed conservatively.
POEM is efficacious and safe for treating achalasia in pediatric populations. Large comparative or randomized trials are warranted to confirm the efficacy and safety of POEM compared to other surgical procedures for achalasia.
贲门失弛缓症是一种罕见的儿童原发性食管动力障碍疾病。经口内镜下肌切开术(POEM)是一种新型内镜技术,已显示出治疗成人贲门失弛缓症的良好效果。然而,目前针对儿科患者的疗效和安全性数据有限。我们进行了系统评价和荟萃分析,以评估 POEM 在儿科贲门失弛缓症中的疗效和安全性。
我们通过 2018 年 7 月检索 MEDLINE、Embase、PubMed 和 Web of Science 数据库。如果研究对儿科患者进行 POEM,则符合纳入标准。主要结局是 POEM 前后的 Eckardt 评分和食管下括约肌(LES)压力。次要结局是与 POEM 相关的临床成功率和不良事件。两名评审员独立审查研究、收集数据,并使用非随机研究方法学指数(MINORS)评估证据质量。使用随机效应荟萃分析计算汇总估计值。使用不一致性统计量来量化异质性,并使用漏斗图评估发表偏倚。
共有 12 项研究纳入了 146 例儿科患者(53.68%为女性),接受 POEM 治疗贲门失弛缓症(疾病平均病程为 19.48 个月)。Eckardt 评分降低了 6.88 分(平均差(MD)6.88,95%置信区间(CI)6.28-7.48,P<0.001),LES 压力降低了 20.73mmHg(MD 20.73,95%CI 15.76-25.70,P<0.001)。POEM 后,至少有 93%的患者短期和长期内经历了贲门失弛缓症症状的改善或缓解,少数患者经历了轻微的不良反应,可以保守治疗。
POEM 治疗儿科贲门失弛缓症是有效且安全的。需要进行大型的比较或随机试验,以确认 POEM 与其他手术治疗贲门失弛缓症相比的疗效和安全性。